SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cheryl Galt who wrote (646)9/3/1997 8:23:00 AM
From: Henry Niman   of 2173
 
Cheryl, Thanks for the clarification. I had read the title and hadn't noticed that the target population had also been expanded. Rezulin is also in a huge prevention trial which should be completed in a couple of years and I suspect that the target population will expand again (although MDs are already writing off label presecriptions according to patients on the diabetes board). Since the drug targets insulin resistance, it makes sense to start treating earlier rather than later. Early treatment offers the potential of delaying or even preventing diabetes itself or subsequent injections for type II patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News